Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer & Lluís Puig. (2023) Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient Preference and Adherence 17, pages 1541-1549.
Read now
Read now
Massimo Travaglini, Julia-Tatjana Maul, Christian Kors, Shirin Zaheri, Jens Gerwien, Michaela Müller, Alan Brnabic, Silvia Sabatino, Christopher Schuster & Tsen-Fang Tsai. (2023) Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO). Clinical, Cosmetic and Investigational Dermatology 16, pages 2971-2983.
Read now
Read now
Neal Bhatia, Jayme Heim, Brad Schenkel & J. Gabriel Vasquez. (2023) Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis. Journal of Dermatological Treatment 34:1.
Read now
Read now
A. A. Hebert, J. Browning, P. C. Kwong, A. M. Duarte, H. N. Price & E. Siegfried. (2022) Managing pediatric psoriasis: update on treatments and challenges—a review. Journal of Dermatological Treatment 33:5, pages 2433-2442.
Read now
Read now
Neil J. Korman, William Malatestinic, Orin M. Goldblum, Mwangi J. Murage, Lisa Renda, Chen-Yen Lin, James Lucas, Chloe Middleton & Steven Lobosco. (2022) Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. Journal of Dermatological Treatment 33:2, pages 733-739.
Read now
Read now
F. Marsili, M. Travaglini, G. Stinco, R. Manzoni, R. Tiberio, F. Prignano, A. Mazzotta, S. P. Cannavò, A. Cuccia, M. Germino, M. R. Bongiorno, S. Persechino, T. Florio, M. Pettinato, M. Tabanelli, R. Sarkar, E. Aloisi, M. Bartezaghi & R. Orsenigo. (2022) Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. Journal of Dermatological Treatment 33:1, pages 401-407.
Read now
Read now
Tessa A. Kouwenhoven, Jeroen A.M. van der Ploeg & Peter C.M. van de Kerkhof. (2020) Treatment goals in psoriasis from a patient perspective: a qualitative study. Journal of Dermatological Treatment 31:1, pages 13-17.
Read now
Read now
G. Carretero, L. Puig, J. M. Carrascosa, L. Ferrándiz, R. Ruiz-Villaverde, P. de la Cueva, I. Belinchon, E. Vilarrasa, R. del Rio, J. L. Sánchez-Carazo, A. López-Ferrer, F. Peral, S. Armesto, N. Eiris, J. Mitxelena, J. Vilar-Alejo, M. A. Martin & C. Soria. (2018) Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. Journal of Dermatological Treatment 29:4, pages 334-346.
Read now
Read now
Jillian Frieder, Dario Kivelevitch, Connie Tran Fiore, Saadeddine Saad & Alan Menter. (2018) The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Review of Clinical Immunology 14:1, pages 1-19.
Read now
Read now
Boni E. Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis & Bruce E. Strober. (2017) Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment 28:6, pages 492-499.
Read now
Read now
Kristian Reich, Craig Leonardi, Mark Lebwohl, Francisco Kerdel, Yukari Okubo, Ricardo Romiti, Orin Goldblum, Ellen B. Dennehy, Lisa Kerr & Howard Sofen. (2017) Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). Journal of Dermatological Treatment 28:4, pages 282-287.
Read now
Read now
A. Simon Pickard, Melinda Gooderham, Susanne Hartz & Claudia Nicolay. (2017) EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Journal of Medical Economics 20:1, pages 19-27.
Read now
Read now
Molly Campa & Alan Menter. (2016) A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. Expert Opinion on Investigational Drugs 25:11, pages 1337-1344.
Read now
Read now
Steven R. Feldman, Donald M. Bushnell, Paul A. Klekotka, Michael Scanlon, Mona L. Martin, Sally W. Wade, Wenjing Yang, Lionel Pinto, Leon Kircik & Hema N. Viswanathan. (2016) Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. Journal of Dermatological Treatment 27:3, pages 224-227.
Read now
Read now
Articles from other publishers (39)
Peter Foley, Kurt Gebauer, John Sullivan, Erin McMeniman, Stephen Shumack, Jonathan Ng, Amelia James, Morton Rawlin, Shireen Sidhu, Dev Tilakaratne, Murray Turner, Barbara Radulski, Peter Nash & Christopher Baker. (2023) Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients. Australasian Journal of Dermatology 64:4, pages 476-487.
Crossref
Crossref
Robert R. McLean, Adam P. Sima, Silky Beaty, Robert Low, Rebecca L. Spitzer, Jeffrey L. Stark, Elizabeth Lesser, Edward Lee & April Armstrong. (2023) Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry. Dermatology and Therapy 13:11, pages 2739-2751.
Crossref
Crossref
Yuxiong Jiang, Ying Li, Dawei Huang, Xiaoyuan Zhong, Qian Yu, Yanhua Liang, Lin Dang, Chengzhi Lv, Binjiang Lin, Furen Zhang, Yunsheng Liang, Jiajing Lu & Yuling Shi. (2023) Quality of Life Benefit and Clinical Predictors of Complete Skin Clearance in Psoriasis: A Multicenter, Prospective, Real-World Study. Dermatology 239:5, pages 802-810.
Crossref
Crossref
Nicole D. Boswell, Madison K. Cook, Esther A. Balogh & Steven R. Feldman. (2022) The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review. Archives of Dermatological Research 315:4, pages 699-706.
Crossref
Crossref
Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih‐Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin & Ron Vender. (2022) Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper. Dermatologic Therapy 35:10.
Crossref
Crossref
M. Gooderham, A. Pinter, L.K. Ferris, R.B. Warren, T. Zhan, J. Zeng, A.M. Soliman, C. Kaufmann, B. Kaplan, H. Photowala & B. Strober. (2022)
Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a
post hoc
integrated analysis of patients with moderate‐to‐severe plaque psoriasis
. Journal of the European Academy of Dermatology and Venereology 36:6, pages 855-865.
Crossref
Crossref
Andrew Blauvelt, Melinda Gooderham, Christopher E. M. Griffiths, April W. Armstrong, Baojin Zhu, Russel Burge, Gaia Gallo, Jiaying Guo, Alyssa Garrelts & Mark Lebwohl. (2022) Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. Dermatology and Therapy 12:3, pages 727-740.
Crossref
Crossref
Georgios Kokolakis, Kasper Vadstrup, Jes B. Hansen & Jose Manuel Carrascosa. (2022) Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. Dermatology 238:4, pages 620-629.
Crossref
Crossref
Georgios Kokolakis, Kasper Vadstrup, Jes B. Hansen & Jose Manuel Carrascosa. (2021) Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors. Dermatology and Therapy 11:6, pages 2027-2042.
Crossref
Crossref
K. Reich, J.B. Hansen, L. Puig, M.P. Konstantinou & R.B. Warren. (2021) Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3. Journal of the European Academy of Dermatology and Venereology 35:10, pages 2034-2044.
Crossref
Crossref
Kim A. Papp, Ahmed M. Soliman, Nicolae Done, Christopher Carley, Esteban Lemus Wirtz & Luis Puig. (2021) Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy 11:4, pages 1291-1304.
Crossref
Crossref
Jo Lambert, Jes Birger Hansen, Anne Sohrt & Luis Puig. (2021) Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy 11:4, pages 1265-1275.
Crossref
Crossref
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, Yan Wang, Yawen Gao, Luis Puig & Matthias Augustin. (2021) Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy 11:3, pages 885-905.
Crossref
Crossref
R.B. Warren, J.B. Hansen, K. Reich, C. Paul & L. Puig. (2020) Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3. Journal of the European Academy of Dermatology and Venereology 35:2, pages 450-457.
Crossref
Crossref
Weiguang Xue, Paranjoy Saharia, Emma Gray, Shoghag Khoudigian-Sinani, Véronique Gaudet, Martin Barbeau & Kim Papp. (2020) Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. Journal of Cutaneous Medicine and Surgery 24:6, pages 561-572.
Crossref
Crossref
J. Seneschal, J.‐P. Lacour, A. Bewley, M. Faurby, C. Paul, G. Pellacani, C. De Simone, L. Horne, A. Sohrt, M. Augustin, E. Hammond & K. Reich. (2020) A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL). Journal of the European Academy of Dermatology and Venereology 34:11, pages 2566-2573.
Crossref
Crossref
Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, Jes B. Hansen, Laura Horne, Carle Paul, Kristian Reich, Julien Seneschal, Clara De Simone, Anne Sohrt, Matthias Augustin & Giovanni Pellacani. (2020) Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). Dermatology and Therapy 10:5, pages 1099-1109.
Crossref
Crossref
Marilyn T. Wan, Rebecca L. Pearl, Zelma C. Chiesa Fuxench, Junko Takeshita & Joel M. Gelfand. (2020) Anticipated and Perceived Stigma Among Patients With Psoriasis. Journal of Psoriasis and Psoriatic Arthritis 5:3, pages 93-99.
Crossref
Crossref
A. Blauvelt, K. Papp, A. GottliebA. JarellK. Reich, C. Maari, K.B. GordonL.K. FerrisR.G. Langley, Y. Tada, R.G. LimaH. ElmaraghyG. GalloL. RendaS.Y. ParkR. BurgeJ. BagelRonald Vender, Mark A. Lomaga, Isabelle Delorme, Chih‐Ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal K. Singh Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, Charles Moon, Lani Clark, Sadra Sasha Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy R. Smith, M. Christine Lee, Stephen Tyring, Patricia Lee, Sunil Dhawan, Craig Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy Owen, Megan Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco Kerdel, Seth B. Forman, Jeffrey Weinberg, Jose Gonzalez‐Chavez, Brent Boyce, Linda Stein‐Gold, Charles Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John Scott, Douglas Young, Jessica Kaffenberger, Kelley Yokum, Matthew Zook, Andrew Blauvelt, Artis Truett, George Schmieder, Gary McCracken, Patrick McElgunn, James Herrmann, Jeffery M. Suchniak, James Appel, Elizabeth Barranco, Mark Lee, Jerry Bagel, Lawrence Osman, Ashley Cauthen, Neil Sadick, Eneida De La Torre, Kelly Taylor, David Cohen, Holly Hake Harris, Jennifer Soung, Vassilios Dimitropoulos, Stephen Miller, Cathy Barnes, Rawan Jumean‐Haddad, Suzanne Bruce, Lawrence Cheung, Scott Guenthner, Anthony Gaspari, Vivian Laquer, James M. Krell, Shahram Jacobs, Walter Nahm, Neil Korman, Boni Elewski, Laura Ferris, Kristina Callis Duffin, David Pariser, Brian Johnson, Paul Wallace, Jeffrey Travers & Richard Fried. (2020) A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. British Journal of Dermatology 182:6, pages 1348-1358.
Crossref
Crossref
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin & Kim Papp. (2020) Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy 10:3, pages 431-447.
Crossref
Crossref
J.M. Norlin, K. Nilsson, U. Persson & M. Schmitt‐Egenolf. (2019) Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals. British Journal of Dermatology 182:4, pages 965-973.
Crossref
Crossref
Finola M. Bruins, Inge M. G. J. Bronckers, Hans M. M. Groenewoud, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong & Marieke M. B. Seyger. (2020) Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients. JAMA Dermatology 156:1, pages 72.
Crossref
Crossref
Kristina Callis Duffin, Andrew G. Bushmakin, Joseph C. Cappelleri, Lotus Mallbris & Carla Mamolo. (2019) A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC Dermatology 19:1.
Crossref
Crossref
Alexander Egeberg & Jacob P. Thyssen. (2019) Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. Journal of the American Academy of Dermatology 81:4, pages 943-949.
Crossref
Crossref
K. Reich, P. RichC. Maari, R. Bissonnette, C. LeonardiA. MenterA. Igarashi, P. KlekotkaD. PatelJ. LiJ. TuttleM. Morgan‐CoxE. Edson‐Heredia, S. FriedrichK. Papp. (2019)
Efficacy and safety of mirikizumab (
LY
3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase
II
study
. British Journal of Dermatology 181:1, pages 88-95.
Crossref
Crossref
Asmah Johar, Suganthi Thevarajah, Agnes Heng, Lee Chin Chan, Chin Chwen Ch’ng, Najeeb Ahmad Mohd Safdar, Pubalan Muniandy, Tarita Taib, Wooi Chiang Tan & Kwee Eng Tey. (2019) Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatology Research and Practice 2019, pages 1-8.
Crossref
Crossref
Bruce E. Strober, Joelle M. van der Walt, April W. Armstrong, Marc Bourcier, Andre V. E. Carvalho, Edgardo Chouela, Arnon D. Cohen, Claudia de la Cruz, Charles N. Ellis, Andrew Y. Finlay, Alice B. Gottlieb, Johann E. Gudjonsson, Lars Iversen, C. Elise Kleyn, Craig L. Leonardi, Charles W. Lynde, Caitriona Ryan, Colin T. Theng, Fernando Valenzuela, Ronald Vender, Jashin J. Wu, Helen S. Young & Alexa B. Kimball. (2018) Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology and Therapy 9:1, pages 5-18.
Crossref
Crossref
April W. Armstrong, Kristian Reich, Peter Foley, Chenglong Han, Michael Song, Yaung-Kaung Shen, Yin You & Kim A. Papp. (2018) Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology 20:1, pages 155-164.
Crossref
Crossref
R.B. WarrenA. BrnabicD. SaureR.G. Langley, K. SeeJ.J. WuA. SchachtL. MallbrisA. Nast. (2018) Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. British Journal of Dermatology 178:5, pages 1064-1071.
Crossref
Crossref
K. Reich, A. Pinter, J.P. Lacour, C. Ferrandiz, G. Micali, L.E. French, M. Lomaga, Y. DutroncC. HennegesS. WilhelmS. HartzC. Paul. (2017) Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. British Journal of Dermatology 177:4, pages 1014-1023.
Crossref
Crossref
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, Chih-ho Hong, Ian Landells, Charles Lynde, Kim Papp, Yves Poulin, Ronald Vender & Marni C. Wiseman. (2017) Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery 21:2_suppl, pages 2S-40S.
Crossref
Crossref
Hema N. Viswanathan, Alex Mutebi, Cassandra E. Milmont, Kenneth Gordon, Hilary Wilson, Hao Zhang, Paul A. Klekotka, Dennis A. Revicki, Matthias Augustin, Gregory Kricorian, Ajay Nirula & Bruce Strober. (2017) Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value in Health 20:8, pages 1174-1179.
Crossref
Crossref
A. Blauvelt, C.E.M. Griffiths, M. Lebwohl, U. Mrowietz, L. Puig, S. Ball, L. Zhang, E. Edson-Heredia, M. Warner, B. Zhu, C-Y. Lin, E. Nikaï, D. Dey, L. Mallbris & K. Reich. (2017) Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. British Journal of Dermatology 177:2, pages 587-590.
Crossref
Crossref
Andrew Blauvelt, Kim A. Papp, Christopher E.M. Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li & Alexa B. Kimball. (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology 76:3, pages 405-417.
Crossref
Crossref
Kenneth B. Gordon, Andrew Blauvelt, Kim A. Papp, Richard G. Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G. Ball, Daniel K. Braun, Gregory S. Cameron, Janelle Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale O. Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris & Craig L. Leonardi. (2016) Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine 375:4, pages 345-356.
Crossref
Crossref
Bruce Strober, Kim A. Papp, Mark Lebwohl, Kristian Reich, Carle Paul, Andrew Blauvelt, Kenneth B. Gordon, Cassandra E. Milmont, Hema N. Viswanathan, Joanne Li, Lionel Pinto, David J. Harrison, Greg Kricorian, Ajay Nirula & Paul Klekotka. (2016) Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology 75:1, pages 77-82.e7.
Crossref
Crossref
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, Herve Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, Carle Paul, Jean-Philippe Lacour, Stephen Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian Kotzin & Ajay Nirula. (2015) Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine 373:14, pages 1318-1328.
Crossref
Crossref
Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, J?rg C. Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo & Kristian Reich. (2015) A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. New England Journal of Medicine 373:2, pages 136-144.
Crossref
Crossref
Junko Takeshita, April W. Armstrong, Philip J. Mease & Joel M. Gelfand. (2015) Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting. The Journal of Rheumatology 42:6, pages 1037-1040.
Crossref
Crossref